\
&
Contact us
\
&
Contact us
Starts in 3 days from now
LocationOnline
ProgrammesThe 9th wave of calls for proposals under the Digital Europe Programme (Work Programme 2025-2027) was published in October and will be open for submission from 4 November 2025 until 3 March 2026.
During this info session, the European Commission will present the three health-related calls that will be open for submission in this wave:
Data ingestion capacities and data services for the European Genomic Data Infrastructure in the European Health Data Space: data storage and processing capacity (DIGITAL-2026-AI-09-DS-HEALTH-STORAGE)
Deployment of cutting-edge multi-modal AI-based solutions in medical imaging (DIGITAL-2026-AI-09-AI-SOLUTIONS-CANCER-STEP)
Organisations potentially interested in the DIGITAL-2026-AI-09-AI-SOLUTIONS-CANCER-STEP topic will have the possibility to present their organisations/ideas in a dedicated pitching session. If you are interested to present in this session, please register in the EU Survey before 12 November 2025.
More information on the event and the call topics, and the possibility to follow the event are available on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
